N/A
Completed N=148
Caregivers' and Physicians' Treatment Preference in Parkinson Patients Treated With Neupro® Requiring Caregiver Support
Source: ClinicalTrials.gov NCT01330290 ↗Enrolled (actual)
148
Serious AEs
0.0%
Results posted
Dec 2013
Primary outcomePrimary: Mean Score of the Caregivers' Rating of Neupro® Compared to Oral Anti-Parkinson Medication — 1.32 units on a scale
Summary
The study objective is to evaluate advantages and disadvantages of Neupro® versus oral anti-Parkinson medication by caregivers and physicians in idiopathic Parkinson's Disease patients requiring caregiver support in nursing home or outpatient care settings.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Mean Score of the Caregivers' Rating of Neupro® Compared to Oral Anti-Parkinson Medication |
1.32 | — |
| PRIMARY Mean Score of the Physicians' Rating of Neupro® Compared to Oral Anti-Parkinson Medication |
1.46 | — |
| SECONDARY Assessment of the Physicians' Rationale for the Choice of Neupro® Due to Substance in Idiopathic Parkinsons Disease Patients Requiring Caregiver Support |
89; 57; 1 | — |
| SECONDARY Assessment of the Physicians' Rationale for the Choice of Neupro® Due to Application Form in Idiopathic Parkinsons Disease Patients Requiring Caregiver Support |
139; 7; 1 | — |
| SECONDARY Score for the Physicians' Rating of Neupro® Compared to Oral Anti-Parkinson Medication in Relation to Dysphagia in Patients With Dysphagia |
1.59 | — |
| SECONDARY Score for the Physicians' Rating of Neupro® Compared to Oral Anti-Parkinson Medication in Relation to Nausea and/or Vomiting in Patients With Nausea and/or Vomiting. |
1.48 | — |
| SECONDARY Score for the Physicians' Rating of Neupro® Compared to Oral Anti-Parkinson Medication in Relation to Control of Compliance |
1.36 | — |
| SECONDARY Score for the Physicians' Rating of Neupro® Compared to Oral Anti-Parkinson Medication in Relation to Multiple Medication in Patients With Multiple Medication |
1.48 | — |
| SECONDARY Score for the Physicians' Rating of Neupro® Compared to Oral Anti-Parkinson Medication in Relation to Surgery Requiring General Anaesthesia |
1.87 | — |
| SECONDARY Score for the Physicians' Rating of Neupro® Compared to Oral Anti-Parkinson Medication in Relation to Dose Adaption |
1.35 | — |
| SECONDARY Score for the Physicians' Rating of Neupro® Compared to Oral Anti-Parkinson Medication With Regard to Independency of Food Administration |
1.50 | — |
| SECONDARY Score for the Physicians' Rating of Neupro® Compared to Oral Anti-Parkinson Medication With Regard to Sleeping Patients |
1.37 | — |
| SECONDARY Score for the Physicians' Rating of Neupro® Compared to Oral Anti-Parkinson Medication in Relation to Risk of Interaction With Other Treatments |
1.15 | — |
| SECONDARY Score for the Physicians' Rating of Neupro® Compared to Oral Anti-Parkinson Medication in Relation to Resorption |
1.64 | — |
| SECONDARY Score for the Caregivers' Rating of Neupro® Compared to Oral Anti-Parkinson Medication in Relation to Dysphagia in Patients With Dysphagia |
1.44 | — |
| SECONDARY Score for the Caregivers' Rating of Neupro® Compared to Oral Anti-Parkinson Medication in Relation to Nausea and/or Vomiting in Patients With Nausea and/or Vomiting |
1.50 | — |
| SECONDARY Score for the Caregivers' Rating of Neupro® Compared to Oral Anti-Parkinson Medication in Relation to Control of Compliance |
1.33 | — |
| SECONDARY Score for the Caregivers' Rating of Neupro® Compared to Oral Anti-Parkinson Medication in Relation to Multiple Medication in Patients With Multiple Medication |
1.49 | — |
| SECONDARY Score for the Caregivers' Rating of Neupro® Compared to Oral Anti-Parkinson Medication With Regard to Independency of Food Administration |
1.54 | — |
| SECONDARY Score for the Caregivers' Rating of Neupro® Compared to Oral Anti-Parkinson Medication With Regard to Sleeping Patients |
1.19 | — |
| SECONDARY Score for the Caregivers' Rating of Neupro® Compared to Oral Anti-Parkinson Medication in Relation to Care-giving Efforts |
1.03 | — |
Eligibility Criteria
Inclusion Criteria
- Only patients having signed the consent form regarding study information, data transfer and data use
- The patients suffer from idiopathic Parkinson's Disease (iPD) treated with a combination of L-dopa or another oral iPD drug and Neupro® for at least one month
- The patients require caregiver support documented as per medical records (e.g. based on German level of care intensity 1 or greater)
- The decision to prescribe Neupro® must have been made by the physician independent of his/her decision to include the patient in the study
Exclusion Criteria
- Patients not fulfilling the inclusion criteria
- And according to Summary of Product Characteristics (SmPC): Hypersensitivity to the active substance or to any of the excipients, magnetic resonance tomography (MRT) or cardioversion
Data sourced from ClinicalTrials.gov (NCT01330290). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.